1. Generics Bulletin
  2. >>Products
  3. >>Generics

Viatris Loses US Challenge To Januvia And Janumet Patents

US Firm May Appeal; Has Appealed Negative USPTO Decision

 
• By Dean Rudge

Viatris’ attempts to deliver US generic versions of sitagliptin and sitagliptin/metformin ahead of patent expiry has failed for now, with an unfavorable judgment from a district court in West Virginia. More than 20 ANDA sponsors have opted to settle litigation with originator Merck.

patents
EU Januvia generics lined up for this month • Source: Shutterstock

Viatris has again been knocked back in its attempt to launch generic versions of Merck & Co’s sitagliptin-containing medicines, Januvia (sitagliptin) and Janumet (sitagliptin/metformin) film-coated tablets, ahead of patent expiry in the US.

A patent-infringement case stemming from its challenges to patents shielding the branded treatments for type 2 diabetes has ended in defeat, with findings of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.